WHO’s Recommendations For Pilot Projects Using World’s First Malaria Vaccine Shows ‘Due Diligence’

The Guardian: World Health Organization right to be wary about first malaria vaccine
Seth Berkley, CEO of Gavi, the Vaccine Alliance, and Mark Dybul, executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria

“…Last week, two advisory bodies to the World Health Organization … recommended against [the new malaria vaccine Mosquirix’s] immediate widespread use, and many people may have been left wondering why. But it was a smart call. … Delivering the vaccine will require unprecedented efforts to inform and mobilize people to bring their children to health clinics at the prescribed time to complete all four doses. … [E]ven if high coverage can be achieved, there is still a danger that news of the vaccine will give people a false sense of security and lead to a reduction in the use of other malaria interventions, which would be tragic. … Mosquirix is no magic bullet and at best may prove to be a useful complementary tool in reducing malaria, but only one of many already being used. All this combined is why the WHO has been so cautious, recommending that we proceed with just a few demonstration projects in three to five settings, and involving around one million children. This is a sensible approach; it is due diligence…” (10/29).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.